Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BLESSED: Expanded Access for DNG64 for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast

Next Previous
Trial Profile

BLESSED: Expanded Access for DNG64 for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 03 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rexin-G (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Basal cell cancer; Carcinoma; Cholangiocarcinoma; Early breast cancer; HER2 positive breast cancer; Non-small cell lung cancer; Osteosarcoma; Pancreatic cancer; Sarcoma; Soft tissue sarcoma; Squamous cell cancer; Triple negative breast cancer
  • Focus Expanded access; Therapeutic Use
  • Acronyms BLESSED

Most Recent Events

  • 04 Jun 2024 Results assessing the effect DeltaRex-G with or without DeltaRex-G Plus (an FDA-approved drug) on advanced chemoresistant pancreatic cancer, sarcoma, and breast cancer, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
  • 02 Aug 2023 Lower age limit for inclusion criteria is increased from 10 to 12 years. Indications are updated to add metastatic carcinoma of breast who have disease progression with standard therapy.
  • 07 Jun 2022 Results (n=3) two years results were presented at the 58th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top